Cardiovascular disease - DiabetesontheNet

Interactive case study: Statin-induced myalgia, secondary prevention of CVD and using non-statin agents

Statin intolerance pathways and non-statin drugs for both primary and secondary prevention.

6 Mar 2024

Diabetes Distilled: Calcium supplementation in people with diabetes – is caution needed?

Increased cardiovascular risk observed in people with diabetes taking regular calcium supplements.

6 Mar 2024

Diabetes Distilled: Type 2 diabetes remission associated with renal and cardiovascular benefits

33–55% lower rates of CKD and 40–49% lower rates of CVD observed in Look AHEAD participants who achieved remission.

6 Mar 2024

Latest news: Tirzepatide prefilled pen; remission and cardiorenal benefits; and low-energy diets in primary care

Stay abreast of the latest news that could impact diabetes nursing.

29 Feb 2024

Diabetes remission provides lasting cardiorenal benefits

Look AHEAD: New analyses reveal additional remission benefits.

22 Jan 2024

Diabetes remission provides lasting cardiorenal benefits

Look AHEAD: New analyses reveal additional remission benefits.

22 Jan 2024

Incretins: How we got here, where we’re at and what is coming next

The incretins, diabetes and cardiorenal disease: an evolving story.

18 Jan 2024

Interactive case study: Primary prevention of cardiovascular disease and use of statins

Assessing cardiovascular risk and using statins to lower it.

10 Jan 2024

Diabetes Distilled: Reaching a XENITH in cardiorenal protection

Phase 2b study demonstrates significant reductions in uACR with developmental drug zibotentan plus dapagliflozin, compared with dapagliflozin alone.

10 Jan 2024

Diabetes Distilled: MACE risk higher in newly diagnosed type 2 diabetes treated with lifestyle alone

Foregoing therapies to reduce glucose, lipids and BP immediately after diagnosis increases MACE risk even if target glycaemic control is achieved.

10 Jan 2024

Diabetes Distilled: DELIVERing reassurance that early eGFR reductions with SGLT2 inhibitors should not prompt drug discontinuation

Initial eGFR reductions of >10% when starting SGLT2 inhibitors are not associated with adverse cardiovascular or renal outcomes.

10 Jan 2024

Editorial: Updates in the management of cardiovascular disease

New drugs, new guidelines: Jane Diggle attempts to cut through the confusion.

7 Nov 2023

At a glance factsheet: Newer lipid-lowering therapies in type 2 diabetes

The newer lipid-lowering therapies available, their different modes of action and their place in treatment.

7 Nov 2023

Diabetes Distilled: 2023 ESC guidelines on cardiovascular disease in patients with type 2 diabetes

Comprehensive guideline covers lifestyle, glycaemic targets, and blood pressure and lipid management.

7 Nov 2023

Latest news: Tirzepatide for type 2 diabetes; cardio-diabetes clinics; and cardiorenal biomarkers in DKD

Stay abreast of the latest news that could impact diabetes nursing.

31 Oct 2023

Meeting report: EASD Annual Meeting 2023

Carefully selected highlights of the recent EASD 2023 meeting.

16 Oct 2023

Cardiorenal biomarkers, canagliflozin and outcomes in DKD

CREDENCE reveals value of biomarkers in predicting complications in DKD.

10 Oct 2023

Cardio-diabetes clinic improving outcomes following heart attack

Joint-speciality clinic improving outcomes of people with diabetes and cardiovascular disease.

2 Oct 2023